- Home
- APDN vs GLTO Comparison
APDN vs GLTO Comparison
Compare APDN & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APDN
- GLTO
- Stock Information
- Founded
- APDN 1983
- GLTO 2011
- Country
- APDN United States
- GLTO Denmark
- Employees
- APDN N/A
- GLTO N/A
- Industry
- APDN Other Consumer Services
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- APDN Consumer Discretionary
- GLTO Health Care
- Exchange
- APDN Nasdaq
- GLTO Nasdaq
- Market Cap
- APDN 4.2M
- GLTO 4.4M
- IPO Year
- APDN N/A
- GLTO 2020
- Fundamental
- Price
- APDN $4.53
- GLTO $3.41
- Analyst Decision
- APDN
- GLTO Buy
- Analyst Count
- APDN 0
- GLTO 1
- Target Price
- APDN N/A
- GLTO $10.00
- AVG Volume (30 Days)
- APDN 151.0K
- GLTO 19.4K
- Earning Date
- APDN 08-07-2025
- GLTO 08-11-2025
- Dividend Yield
- APDN N/A
- GLTO N/A
- EPS Growth
- APDN N/A
- GLTO N/A
- EPS
- APDN N/A
- GLTO N/A
- Revenue
- APDN $3,790,616.00
- GLTO N/A
- Revenue This Year
- APDN $57.08
- GLTO N/A
- Revenue Next Year
- APDN $40.00
- GLTO N/A
- P/E Ratio
- APDN N/A
- GLTO N/A
- Revenue Growth
- APDN N/A
- GLTO N/A
- 52 Week Low
- APDN $4.37
- GLTO $2.01
- 52 Week High
- APDN $2,655.00
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- APDN 33.61
- GLTO 58.60
- Support Level
- APDN $4.51
- GLTO $3.10
- Resistance Level
- APDN $5.20
- GLTO $3.61
- Average True Range (ATR)
- APDN 0.52
- GLTO 0.25
- MACD
- APDN 0.45
- GLTO -0.00
- Stochastic Oscillator
- APDN 26.36
- GLTO 58.76
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.